Mark S. Graham

Array ( [id] => 5813110 [patent_doc_number] => 20060083739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-04-20 [patent_title] => 'Treating prostate cancer with anti-ErbB2 antibodies' [patent_app_type] => utility [patent_app_number] => 11/234586 [patent_app_country] => US [patent_app_date] => 2005-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 31526 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0083/20060083739.pdf [firstpage_image] =>[orig_patent_app_number] => 11234586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5742815 [patent_doc_number] => 20060088540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-04-27 [patent_title] => 'Antagonists and methods for inhibiting angiogenesis' [patent_app_type] => utility [patent_app_number] => 11/227524 [patent_app_country] => US [patent_app_date] => 2005-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 16317 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20060088540.pdf [firstpage_image] =>[orig_patent_app_number] => 11227524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5720761 [patent_doc_number] => 20060073536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-04-06 [patent_title] => 'Immunoassays for determining vitamin B12, and reagents and kits therefor' [patent_app_type] => utility [patent_app_number] => 11/225818 [patent_app_country] => US [patent_app_date] => 2005-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5973 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0073/20060073536.pdf [firstpage_image] =>[orig_patent_app_number] => 11225818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4547776 [patent_doc_number] => 07820180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-26 [patent_title] => 'Listeria-based and LLO-based vaccines' [patent_app_type] => utility [patent_app_number] => 11/223945 [patent_app_country] => US [patent_app_date] => 2005-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 18758 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/820/07820180.pdf [firstpage_image] =>[orig_patent_app_number] => 11223945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5727497 [patent_doc_number] => 20060058257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-03-16 [patent_title] => 'Influencing angiogenesis using CD66a' [patent_app_type] => utility [patent_app_number] => 11/224162 [patent_app_country] => US [patent_app_date] => 2005-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7684 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0058/20060058257.pdf [firstpage_image] =>[orig_patent_app_number] => 11224162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5710004 [patent_doc_number] => 20060051349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-03-09 [patent_title] => 'Immunotherapy of autoimmune disorders using antibodies which target B-cells' [patent_app_type] => utility [patent_app_number] => 11/222838 [patent_app_country] => US [patent_app_date] => 2005-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7355 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0051/20060051349.pdf [firstpage_image] =>[orig_patent_app_number] => 11222838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 344845 [patent_doc_number] => 07498030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-03-03 [patent_title] => 'Treatment with anti-ErbB2 antibodies and anti-hormonal compounds' [patent_app_type] => utility [patent_app_number] => 11/222587 [patent_app_country] => US [patent_app_date] => 2005-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 36344 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/498/07498030.pdf [firstpage_image] =>[orig_patent_app_number] => 11222587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5799311 [patent_doc_number] => 20060034842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-16 [patent_title] => 'Treatment with anti-ErbB2 antibody combinations' [patent_app_type] => utility [patent_app_number] => 11/223361 [patent_app_country] => US [patent_app_date] => 2005-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 36349 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20060034842.pdf [firstpage_image] =>[orig_patent_app_number] => 11223361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4484510 [patent_doc_number] => 07883702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-02-08 [patent_title] => 'Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies' [patent_app_type] => utility [patent_app_number] => 11/661134 [patent_app_country] => US [patent_app_date] => 2005-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 36 [patent_no_of_words] => 17005 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/883/07883702.pdf [firstpage_image] =>[orig_patent_app_number] => 11661134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4634022 [patent_doc_number] => 08012470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-09-06 [patent_title] => 'Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies' [patent_app_type] => utility [patent_app_number] => 11/186136 [patent_app_country] => US [patent_app_date] => 2005-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6801 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/012/08012470.pdf [firstpage_image] =>[orig_patent_app_number] => 11186136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5767787 [patent_doc_number] => 20060019344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-01-26 [patent_title] => 'C-erbB-2 external domain: gp75' [patent_app_type] => utility [patent_app_number] => 11/175405 [patent_app_country] => US [patent_app_date] => 2005-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 20586 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0019/20060019344.pdf [firstpage_image] =>[orig_patent_app_number] => 11175405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 363204 [patent_doc_number] => 07482014 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-01-27 [patent_title] => 'Melanoma therapy' [patent_app_type] => utility [patent_app_number] => 11/166862 [patent_app_country] => US [patent_app_date] => 2005-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4341 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/482/07482014.pdf [firstpage_image] =>[orig_patent_app_number] => 11166862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 215113 [patent_doc_number] => 07618631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-11-17 [patent_title] => 'Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs' [patent_app_type] => utility [patent_app_number] => 11/154465 [patent_app_country] => US [patent_app_date] => 2005-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 35925 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/618/07618631.pdf [firstpage_image] =>[orig_patent_app_number] => 11154465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7069034 [patent_doc_number] => 20050244417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-11-03 [patent_title] => 'Apo-2 ligand-anti-Her-2 antibody synergism' [patent_app_type] => utility [patent_app_number] => 11/153056 [patent_app_country] => US [patent_app_date] => 2005-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14826 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0244/20050244417.pdf [firstpage_image] =>[orig_patent_app_number] => 11153056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5793138 [patent_doc_number] => 20060013819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-01-19 [patent_title] => 'Therapy of platinum-resistant cancer' [patent_app_type] => utility [patent_app_number] => 11/154337 [patent_app_country] => US [patent_app_date] => 2005-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 32031 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0013/20060013819.pdf [firstpage_image] =>[orig_patent_app_number] => 11154337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368385 [patent_doc_number] => 20090305944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'Methods for Providing Palliative Care with AVR 118' [patent_app_type] => utility [patent_app_number] => 11/921484 [patent_app_country] => US [patent_app_date] => 2005-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6601 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0305/20090305944.pdf [firstpage_image] =>[orig_patent_app_number] => 11921484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7111112 [patent_doc_number] => 20050208567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-09-22 [patent_title] => 'Reagents and methods useful for detecting diseases of the prostate' [patent_app_type] => utility [patent_app_number] => 11/122741 [patent_app_country] => US [patent_app_date] => 2005-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 33914 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0208/20050208567.pdf [firstpage_image] =>[orig_patent_app_number] => 11122741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6925364 [patent_doc_number] => 20050238619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-10-27 [patent_title] => 'Method for the delivery of sustained release agents' [patent_app_type] => utility [patent_app_number] => 11/082851 [patent_app_country] => US [patent_app_date] => 2005-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3249 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0238/20050238619.pdf [firstpage_image] =>[orig_patent_app_number] => 11082851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7514926 [patent_doc_number] => 08038996 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-10-18 [patent_title] => 'Composition and method for cancer treatment' [patent_app_type] => utility [patent_app_number] => 11/075891 [patent_app_country] => US [patent_app_date] => 2005-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 11071 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/038/08038996.pdf [firstpage_image] =>[orig_patent_app_number] => 11075891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5085335 [patent_doc_number] => 20070275386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-29 [patent_title] => 'Polymorphisms in the Epidermal Growth Factor Receptor Gene Promoter' [patent_app_type] => utility [patent_app_number] => 10/591228 [patent_app_country] => US [patent_app_date] => 2005-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17047 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20070275386.pdf [firstpage_image] =>[orig_patent_app_number] => 10591228 [rel_patent_id] =>[rel_patent_doc_number] =>)